HEALTHCARE COMPLIANCE POLICY Effective Date: May 20, 2013 Version: 3 Policy No.: VRX-US-CMP-001 Approved by: VP, Chief Compliance Officer and

First Page		Document Content
Date: 2014-04-23 14:54:54 Companies listed on the New York Stock Exchange Valeant Pharmaceuticals Pharmaceutical industry Pharmaceutical Research and Manufacturers of America Chief compliance officer Compliance training American Medical Association Pharmacology Pharmaceutical sciences Corporate governance Regulatory compliance		HEALTHCARE COMPLIANCE POLICY Effective Date: May 20, 2013 Version: 3 Policy No.: VRX-US-CMP-001 Approved by: VP, Chief Compliance Officer and Add to Reading List Source URL: www.valeant.com Download Document from Source Website File Size: 179,15 KB Share Document on Facebook

	PDF Document DocID: 1xvUb - View Document
	PDF Document DocID: 1xc8R - View Document
	Institute of Pharmacology www.pki.unibe.ch Introduction Prof. Dr. Dr. Stephan von Gunten MD PhD MME DocID: 1vqsj - View Document
	Jansone et al.: Intrinsic Activity, 2017; 5 (Suppl.2):A1.6 doi:IA.5.S2-A1.6 published online: 16 October 2017 2nd International Conference in Pharmacology: From Cellular Processes to Drug Targets Rīga, Latvia DocID: 1vlJU - View Document
	Human cells Notable for research in: -Medecine: Diseases and cancers -Cell Biology -Pharmacology DocID: 1vk1K - View Document